Urotensin II: The Most Potent Vasoconstrictor in Mammals
Cardiovascular Peptides
10× Stronger
Urotensin II constricts blood vessels with potency an order of magnitude greater than endothelin-1, making it the most powerful vasoconstrictor identified in mammals.
Ames et al., Nature, 1999
Ames et al., Nature, 1999
View as imageIn 1999, two research teams independently identified human urotensin II (UII) as the endogenous ligand for GPR14, an orphan G-protein-coupled receptor expressed primarily in cardiovascular tissue. The finding was remarkable for two reasons. First, UII turned out to be the most potent vasoconstrictor ever identified in mammals, constricting blood vessels with potency an order of magnitude greater than endothelin-1, the previous record holder. Second, UII was not a new molecule. It had been known to fish biologists for decades as a peptide from the caudal neurosecretory system of teleost fish. That a fish peptide would turn out to be the most powerful blood vessel constrictor in human biology was unexpected, and the implications for cardiovascular disease are still being worked out.
Adrenomedullin, which relaxes blood vessels, represents the opposite end of the vasoactive peptide spectrum from UII.
Key Takeaways
- Urotensin II is an 11-amino-acid cyclic peptide originally isolated from goby fish spinal cords, later cloned from humans
- Ames et al. (1999, Nature) demonstrated UII constricts blood vessels with potency 10 times greater than endothelin-1
- UII acts through the UT receptor (formerly GPR14), a G-protein-coupled receptor predominantly expressed in cardiovascular, renal, and central nervous system tissue
- Plasma UII levels and myocardial UII expression are elevated in end-stage congestive heart failure (Dschietzig et al., 2002)
- UII promotes cardiac fibrosis, cardiomyocyte hypertrophy, and vascular smooth muscle cell proliferation under pathological conditions (Tzanidis et al., 2003)
- No UT receptor antagonist has reached clinical approval, though preclinical research has demonstrated therapeutic potential
From Fish to Human: An Evolutionary Surprise
Urotensin II was first isolated from the urophysis (caudal neurosecretory organ) of the goby fish in the 1960s. In fish, UII plays a role in osmoregulation, controlling salt and water balance. The peptide was considered a curiosity of comparative endocrinology, relevant to fish physiology but assumed to have no human equivalent.
That assumption was wrong. In 1998-1999, the human gene encoding UII was cloned, and the peptide was identified as the natural ligand for GPR14, an orphan receptor whose function had been unknown. Ames et al. (1999) published the landmark finding in Nature: human urotensin-II is a potent vasoconstrictor and agonist for GPR14.[1] Independently, Liu et al. (1999) identified UII as the endogenous ligand for GPR14 through a different experimental approach, confirming the receptor pairing.[2]
The receptor was subsequently renamed the UT receptor. The human form of UII is an 11-amino-acid cyclic peptide with a disulfide bridge that creates a ring structure essential for biological activity. The cyclic portion contains a conserved sequence (Cys-Phe-Trp-Lys-Tyr-Cys) that is virtually identical between fish and humans, suggesting the peptide has been functionally important for at least 400 million years of vertebrate evolution.
The Vasoconstriction Record
The defining characteristic of UII is its extraordinary vasoconstrictor potency. In isolated human arterial preparations, UII constricts blood vessels with an EC50 (the concentration producing half-maximal effect) approximately 10 times lower than endothelin-1. This made UII the most potent mammalian vasoconstrictor identified at the time of its discovery, a distinction it retains.
The vasoconstriction is not uniform across all vascular beds. UII shows regional selectivity, with particularly strong effects on coronary, pulmonary, and renal vasculature. In some vascular beds, UII actually causes vasodilation rather than constriction, depending on the balance of endothelial and smooth muscle receptor activation. This complexity has made studying UII's overall hemodynamic effects challenging.
Zhu et al. (2006) published a comprehensive review of UII in cardiovascular and renal physiology, noting that through stimulation of Gαq-coupled UT receptors, UII mediates contraction of vascular smooth muscle and endothelial-dependent vasorelaxation, and positive inotropy in the human right atrium and ventricle.[3] The dual capacity for both constriction and relaxation, depending on the vascular bed and the presence of intact endothelium, explains why systemic administration of UII does not simply cause a massive blood pressure spike.
UII in Heart Failure
The clinical relevance of UII became apparent when researchers measured its levels in patients with cardiovascular disease. Dschietzig et al. (2002) measured plasma UII levels and cardiovascular gene expression in patients with congestive heart failure.[4] They found that myocardial UII expression is strongly upregulated in end-stage heart failure, with increased UII binding sites in failing heart tissue. Plasma levels of UII were also elevated, suggesting the peptide circulates at higher concentrations when the heart is failing.
Nakayama et al. (2008) documented a significant 75% increase in UT receptor gene expression in the hearts of rats with congestive heart failure after myocardial infarction.[5] Both the peptide and its receptor are upregulated in cardiac disease, a pattern that suggests UII signaling is actively amplified in the failing heart, potentially contributing to disease progression.
Whether elevated UII is a cause of heart failure progression or a compensatory response to it remains debated. The vasoconstriction hypothesis suggests that elevated UII worsens heart failure by increasing afterload (the resistance the heart must pump against). The compensatory hypothesis suggests that UII's positive inotropic effects (increasing contractile force) may initially help maintain cardiac output, even though sustained UII signaling eventually becomes pathological.
Direct Effects on the Heart
Beyond vasoconstriction, UII has direct effects on cardiac tissue that contribute to pathological remodeling.
Tzanidis et al. (2003) demonstrated that UII directly acts on the heart to promote cardiac fibrosis and hypertrophy.[6] UII stimulated collagen synthesis by cardiac fibroblasts, a process that leads to the stiffening and scarring of heart muscle. It also promoted cardiomyocyte hypertrophy, the pathological enlargement of heart muscle cells that occurs when the heart is chronically overworked. These direct cardiac effects are mediated through UT receptors on cardiac fibroblasts and cardiomyocytes, independent of UII's vascular effects.
Russell (2004) reviewed the emerging roles of UII in cardiovascular disease and summarized the pathophysiological picture: under disease conditions, UII contributes to cardiomyocyte hypertrophy, extracellular matrix production, enhanced vasoconstriction, vascular smooth muscle cell hyperplasia, and endothelial cell hyper-permeability.[7] Each of these processes contributes to the progression of heart failure, atherosclerosis, or pulmonary hypertension.
UII Beyond the Heart
The UT receptor system is not limited to the heart and blood vessels. Matsushita et al. (2001) mapped the distribution of UII and its receptor across human tissues and found co-expression in cardiovascular, renal, and central nervous system tissue.[8]
In the kidneys, UII affects renal blood flow, sodium handling, and tubular function. Mallamaci et al. (2005) studied UII in patients with end-stage renal disease and found an inverse correlation between UII levels and sympathetic nervous system function, suggesting that UII and the sympathetic system interact in ways that affect blood pressure and fluid balance in kidney failure.[9]
In the lungs, UII contributes to pulmonary vascular tone and may play a role in pulmonary hypertension. In the central nervous system, UII has been implicated in sleep-wake regulation, anxiety-like behavior, and metabolic control. UII also appears to play a role in glucose and lipid metabolism, with evidence suggesting that UT receptor activation influences insulin secretion and fatty acid oxidation. This metabolic dimension connects UII to the broader network of peptides that regulate energy balance, though UII's metabolic effects are less well characterized than its cardiovascular ones.
This broad tissue distribution means that pharmacological targeting of the UT receptor will inevitably affect multiple organ systems, complicating drug development. A UT receptor antagonist designed to reduce cardiac fibrosis might simultaneously affect renal sodium handling, pulmonary vascular tone, and central nervous system function in unpredictable ways.
Therapeutic Potential: UT Receptor Antagonists
The UT receptor is a validated therapeutic target. If UII contributes to cardiac fibrosis, hypertrophy, vasoconstriction, and vascular remodeling, then blocking the UT receptor should theoretically slow or reverse these processes.
Several UT receptor antagonists have been developed and tested in preclinical models. Paltrinieri (peptide-based antagonists like urantide) and small-molecule antagonists have shown promise in animal models of heart failure, atherosclerosis, and pulmonary hypertension. In preclinical studies, urantide combined with exercise training reduced doxorubicin-induced cardiotoxicity, demonstrating that UT receptor blockade can protect the heart from chemical injury.
Ross et al. (2010) reviewed the role of UII in health and disease and concluded that the UT receptor system represents a potential therapeutic target for cardiac, pulmonary, and renal diseases.[10]
An alternative therapeutic approach involves using UII itself or UT agonists in controlled contexts. Because UII causes vasodilation in some vascular beds (when the endothelium is intact), there is theoretical interest in harnessing this effect for conditions like pulmonary hypertension, where selective vasodilation of pulmonary vessels would be beneficial. This approach has not advanced beyond conceptual discussion, but it illustrates the complexity of a system where the same peptide can constrict or relax blood vessels depending on the context.
Despite this preclinical evidence, no UT receptor antagonist has reached clinical approval. The challenges are multiple: the dual vasoconstrictor/vasodilator activity of UII makes predicting net hemodynamic effects difficult; the broad tissue distribution of UT receptors raises concerns about off-target effects; and the exact contribution of UII to human cardiovascular disease pathology has been difficult to quantify because no selective UT antagonist has been tested in large human trials.
Pereira-Castro et al. (2019) provided the most recent comprehensive review of UII in cardiovascular disease, integrating two decades of research into a framework that positions UII as both a biomarker and a therapeutic target, while acknowledging that clinical translation has been slower than the preclinical data would suggest.[11]
Why UII Remains "Mysterious"
Two decades after its identification as a human cardiovascular peptide, UII occupies an unusual position in peptide biology. Its pharmacological potency is extreme. Its association with heart failure is well-documented. Its direct effects on cardiac remodeling have been characterized in detail. Multiple research groups have proposed UT receptor antagonism as a therapeutic strategy.
Yet no drug targeting this system has reached patients. The gap between preclinical promise and clinical reality reflects the complexity of translating vasoactive peptide biology into therapy. Angiotensin II, another vasoconstrictor peptide, required decades of research before ACE inhibitors and angiotensin receptor blockers became standard cardiovascular treatments. Bradykinin's role in cardiovascular medicine was also understood long before it was therapeutically exploited. UII may follow a similar trajectory, but the timeline remains uncertain.
The peptide that started as a fish osmoregulatory factor and turned out to be the most potent vasoconstrictor in human biology still has not yielded a therapeutic product. Whether it will depends on whether UT receptor antagonists can navigate the challenges of clinical development in cardiovascular disease, a space where even well-validated targets frequently fail in late-stage trials.
The Bottom Line
Urotensin II, an 11-amino-acid cyclic peptide conserved from fish to humans, is the most potent vasoconstrictor identified in mammals, exceeding endothelin-1 by an order of magnitude. Acting through the UT receptor (GPR14), UII promotes cardiac fibrosis, cardiomyocyte hypertrophy, and vascular remodeling under pathological conditions. UII and its receptor are upregulated in heart failure, renal disease, and pulmonary hypertension. Despite two decades of research identifying the UT receptor as a therapeutic target, no antagonist has reached clinical approval. The complexity of UII's dual vasoconstrictor/vasodilator activity and broad tissue distribution has slowed clinical translation.